Hinova Pharmaceuticals Inc. (SHA:688302)

Hinova Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	313.7	438.18	633.44	813.23	1,202	901.22
Short-Term Investments	-	109.16	-	-	-	-
Trading Asset Securities	471.02	310.59	210.49	290.62	366.24	-
Cash & Short-Term Investments	784.73	857.93	843.93	1,104	1,568	901.22
Cash Growth	-18.64%	1.66%	-23.55%	-29.59%	73.97%	-20.85%
Accounts Receivable	13.35	0	-	-	-	-
Other Receivables	0.68	0.51	0.84	1.39	1.67	0.54
Receivables	14.03	0.52	0.84	1.39	1.67	0.54
Inventory	15.29	2.85	0	0.01	0.01	0
Prepaid Expenses	-	-	-	-	-	13.09
Other Current Assets	42.24	45.05	40.77	41.99	41.78	40.38
Total Current Assets	856.28	906.34	885.54	1,147	1,611	955.24
Property, Plant & Equipment	367.19	356.03	328.62	187.99	86.61	12.72
Long-Term Investments	17.41	13.8	113.09	109.98	5	-
Other Intangible Assets	30.8	31.08	30.56	31.21	31.86	-
Long-Term Deferred Charges	-	-	-	0.04	0.08	-
Other Long-Term Assets	1.39	2.51	3.77	15.12	0.21	14.39
Total Assets	1,273	1,310	1,362	1,492	1,735	982.35

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	14.34	4.58	40.63	3.14	2.29	1.31
Accrued Expenses	48.92	38.95	31.09	49.17	69.81	90.45
Short-Term Debt	-	-	-	-	30	-
Current Portion of Leases	3.07	3.3	3.22	3.77	2.45	2.8
Current Unearned Revenue	0.72	3.8	-	-	-	-
Other Current Liabilities	71.67	75.29	72.01	50.76	33.73	96.77
Total Current Liabilities	138.72	125.9	146.95	106.84	138.27	191.33
Long-Term Debt	100	100	-	-	-	-
Long-Term Leases	1.69	2.59	5.83	9.08	3.31	1.11
Long-Term Unearned Revenue	24.42	17.49	16.55	8.55	8.1	1.15
Other Long-Term Liabilities	0.76	0.2	-	-	-	-
Total Liabilities	265.59	246.19	169.33	124.47	149.68	193.59

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	99.02	99.02	99.02	99.02	99.02	74.26
Additional Paid-In Capital	2,592	2,592	2,583	2,558	2,482	1,409
Retained Earnings	-1,683	-1,627	-1,490	-1,290	-996.06	-694.54
Comprehensive Income & Other	-0.29	-0.15	-0.03	0.11	0.14	-0.07
Total Common Equity	1,007	1,064	1,192	1,367	1,585	788.76
Shareholders' Equity	1,007	1,064	1,192	1,367	1,585	788.76
Total Liabilities & Equity	1,273	1,310	1,362	1,492	1,735	982.35

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	104.76	105.89	9.05	12.85	35.76	3.91
Net Cash (Debt)	679.96	752.04	834.88	1,091	1,532	897.31
Net Cash Growth	-20.66%	-9.92%	-23.48%	-28.79%	70.74%	-21.16%
Net Cash Per Share	6.93	7.62	8.41	11.02	16.87	12.07
Filing Date Shares Outstanding	99.02	99.02	99.02	99.02	99.02	74.26
Total Common Shares Outstanding	99.02	99.02	99.02	99.02	99.02	74.26
Working Capital	717.56	780.43	738.59	1,040	1,473	763.91
Book Value Per Share	10.17	10.74	12.04	13.81	16.01	10.62
Tangible Book Value	976.67	1,032	1,162	1,336	1,554	788.76
Tangible Book Value Per Share	9.86	10.43	11.73	13.49	15.69	10.62
Buildings	76.25	76.25	-	-	-	-
Machinery	72.92	22.02	17.15	15.49	14.85	11.16
Construction In Progress	232.08	267.36	314.5	169.54	73.76	3

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 22, 2026

Data Sources Report a data error